Chen, M. et al. (2013) Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex. Journal of the National Cancer Institute, 105(6), pp. 405-423. (doi: 10.1093/jnci/djt006) (PMID:23446755) (PMCID:PMC3601953)
|
Text
78847.pdf - Published Version Available under License Creative Commons Attribution Non-commercial. 22MB |
Abstract
Background: Imatinib mesylate (IM) induces clinical remission of chronic myeloid leukemia (CML). The Abelson helper integration site 1 (AHI-1) oncoprotein interacts with BCR-ABL and Janus kinase 2 (JAK2) to mediate IM response of primitive CML cells, but the effect of the interaction complex on the response to ABL and JAK2 inhibitors is unknown. Methods: The AHI-1–BCR-ABL–JAK2 interaction complex was analyzed by mutational analysis and coimmunoprecipitation. Roles of the complex in regulation of response or resistance to ABL and JAK2 inhibitors were investigated in BCR-ABL + cells and primary CML stem/progenitor cells and in immunodeficient NSG mice. All statistical tests were two-sided. Results: The WD40-repeat domain of AHI-1 interacts with BCR-ABL, whereas the N-terminal region interacts with JAK2; loss of these interactions statistically significantly increased the IM sensitivity of CML cells. Disrupting this complex with a combination of IM and an orally bioavailable selective JAK2 inhibitor (TG101209 [TG]) statistically significantly induced death of AHI-1–overexpressing and IM-resistant cells in vitro and enhanced survival of leukemic mice, compared with single agents (combination vs TG alone: 63 vs 53 days, ratio = 0.84, 95% confidence interval [CI] = 0.6 to 1.1, P = .004; vs IM: 57 days, ratio = 0.9, 95% CI = 0.61 to 1.2, P = .003). Combination treatment also statistically significantly enhanced apoptosis of CD34+ leukemic stem/progenitor cells and eliminated their long-term leukemia-initiating activity in NSG mice. Importantly, this approach was effective against treatment-naive CML stem cells from patients who subsequently proved to be resistant to IM therapy. Conclusions: Simultaneously targeting BCR-ABL and JAK2 activities in CML stem/progenitor cells may improve outcomes in patients destined to develop IM resistance.
Item Type: | Articles |
---|---|
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Holyoake, Professor Tessa and Gallipoli, Dr Paolo and Jorgensen, Dr Heather and Paul, Mr James and Stobo, Mr Jon |
Authors: | Chen, M., Gallipoli, P., DeGeer, D., Sloma, I., Forrest, D.L., Chan, M., Lai, D., Jorgensen, H., Ringrose, A., Wang, H.M., Lambie, K., Nakamoto, H., Saw, K.M., Turhan, A., Arlinghaus, R., Paul, J., Stobo, J., Barnett, M.J., Eaves, A., Eaves, C.J., Holyoake, T.L., and Jiang, X. |
College/School: | College of Medical Veterinary and Life Sciences > School of Cancer Sciences |
Journal Name: | Journal of the National Cancer Institute |
Journal Abbr.: | JNCI |
Publisher: | Oxford University Press |
ISSN: | 0027-8874 |
ISSN (Online): | 1460-2105 |
Published Online: | 27 February 2013 |
Copyright Holders: | Copyright © 2013 The Authors |
First Published: | First published in Journal of the National Cancer Institute 105(6):405-423 |
Publisher Policy: | Reproduced under a Creative Commons License |
University Staff: Request a correction | Enlighten Editors: Update this record